Regioselective 2-hydroxylation of 17β-estradiol by rat cytochrome P4501B1

Toxicology and Applied Pharmacology

Volumn 216, Issue 3, 2006, Pages 469-478

  Rahman, Mostafizur ^a,b   Hayes Sutter, Carrie ^a   Emmert, Gary L ^b   Sutter, Thomas R ^a,b  

^a UNIVERSITY OF MEMPHIS   (United States)

^b University of Memphis   (United States)

Author keywords

2,4,3 ,5 Tetramethoxystilbene; 2 Hydroxyestradiol; 4 Hydroxyestradiol; 7,8 Benzoflavone; Carcinogenesis; Cytochrome P4501B1; Estrogen metabolism

Indexed keywords

2 HYDROXYESTRADIOL; 4 HYDROXYESTRADIOL; ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 1B1; CYTOCHROME P450 INHIBITOR; ESTRADIOL; OXYGENASE; STILBENE DERIVATIVE;

ARTICLE; CARCINOGENESIS; CATALYSIS; CONTROLLED STUDY; HUMAN; HYDROXYLATION; KINETICS; MICHAELIS MENTEN KINETICS; NONHUMAN;

ADRENAL GLANDS; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCHEMISTRY; ENZYME INHIBITORS; ESTRADIOL; HUMANS; HYDROXYLATION; MICROSOMES; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; STILBENES;

ANIMALIA;

EID: 33750051690     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.06.004     Document Type: Article

References (61)

1. Bhattacharyya K.K., Brakes P.B., Eltoms S.E., Otto S.A., and Jefcoate C.R. Identification of rat adrenal cytochrome P450 active in polycyclic hydrocarbon metabolism as rat CYP1B1. Demonstration of a unique tissue-specific pattern of hormonal and aryl hydrocarbon receptor-linked regulation. J. Biol. Chem. 270 (1995) 11595-11602
2. Buters J.T., Sakai S., Richter T., Pineau T., Alexander D.L., Savas U., Doehmer J., Ward J.M., Jefcoate C.R., and Gonzalez F.J. Cytochrome P450 CYP1B1 determines susceptibility to 7,12 dimethylbenz[a]anthracene-induced lymphomas. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1977-1982
3. Carnell D.M., Smith R.E., Daley F.M., Barber P.R., Hoskin P.J., Wilson G.D., Murray G.I., and Everett S.A. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int. J. Radiat. Oncol., Biol., Phys. 58 (2004) 500-509
4. Cavalieri E.L., Stack D.E., Devanesan P.D., Todorovic R., Dwivedy I., Higgingbotham S., Johansson S.L., Patil K.D., Gross M.L., Gooden J.K., Ramanathan R., Cerny R.L., and Rogan E.G. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10937-10942
5. Chakravarti D., Mailander P.C., Higginbotham S., Cavalieri E.L., and Rogan E.G. The catechol estrogen-3,4-quinone metabolites induce mutations in the mammary gland of ACI rats. Proc. Am. Assoc. Cancer Res. 44 (2003) 180
6. Chan H.Y., Wang H., and Leung L.K. The red clover (Trifolium pretense) isoflavone biochanin A modulates the biotransformation pathways of 7,12-dimethyl benzo[a]anthrance. Br. J. Nutr. 90 (2003) 87-92
7. Chang T.K.H., Chen J., and Lee W.B.K. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J. Pharmacol. Exp. Ther. 299 (2001) 874-882
8. Chang T.K., Chen J., Pillay V., Ho J.Y., and Bandiera S.M. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol. Sci. 71 (2003) 11-19
9. Choudhary D., Jansson I., Stoilov I., Sarfarazi M., and Schenkman J.B. Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch. Biochem. Biophys. 436 (2005) 50-61
10. Chun Y.J., and Kim S. Discovery of cytochrome P4501B1 inhibitors as new promising anti-cancer agents. Med. Res. Rev. 23 (2003) 657-668
11. Chun Y.J., Kim S., Kim D., Lee S.K., and Guengerich F.P. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 61 (2001) 8164-8170
12. Dawling S., Hachey D.L., Roodi N., and Parl F.F. In vitro model of mammary estrogen metabolism: structural and kinetic differences between catechol estrogens 2- and 4-hydroxyestradiol. Chem. Res. Toxicol. 17 (2004) 1258-1264
13. DBP/ICR Analytical methods manual, USEPA, Office of Water 1996 EPA 814-B-96-00.
14. Dixon M. The determination of enzyme inhibitor constants. Biochem. J. 55 (1953) 170-171
15. Don M.J., Lewis D.F.V., Wang S.Y., Tsai M.W., and Ueng Y.F. Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2 and CYP1B1. Bioorg. Med. Chem. Lett. 13 (2003) 2535-2538
16. Doostdar H., Burke M.D., and Mayer R.T. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144 (2000) 31-38
17. Downie D., Rooney P.H., McFadyen M.C.E., and Murray G.I. Pharmacogenomics of cytochrome P450 enzymes in tumors. Current Pharmacogenomics 2 (2004) 243-254
18. Dunning A.M., Dowsett M., Healey C.S., Tee L., Luben R.N., Folkerd E., Novik K.L., Kelemen L., Ogata S., Pharoah P.D.P., Easton D.F., Day N.E., and Ponder B.A.J. Polymorphism associated with circulating sex hormone levels in postmenopausal women. J. Natl. Cancer Inst. 96 (2004) 936-945
19. Federal Register Environmental Documents-guidelines establishing test procedures for the analysis of pollutants; procedures for detection and quantitation. 2003. 40 CFR Part 136, USEPA 68, 11770-11790.
20. Fernandez S.V., Russo I.H., and Russo J. Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int. J. Cancer 118 (2006) 1862-1868
21. Glaser J.A., Forest D.L., McKee G.D., Quave S.A., and Budde W.L. Trace analyses for wastewaters. Environ. Sci. Technol. 15 (1981) 1426-1435
22. Green M.D., Jiang X., and King C.D. Inhibition of human hepatic CYP isoforms by mGluR5 antagonists. Life Sci. 75 (2004) 947-953
23. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14 (2001) 611-650
24. Hanna I.H., Dawling S., Roodi N., Guengerich F.P., and Parl F.F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 60 (2000) 3440-3444
25. Hayes C.L., Spink D.C., Spink B.C., Cao J.Q., Walker N.J., and Sutter T.R. 17β-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9776-9781
26. He X., Cryles M.J., De Voss J.J., and Ortiz de Montellano P.R. Calibration of the channel that determines the ω-hydroxylation regiospecificity of cytochrome P4504A1. J. Biol. Chem. 280 (2005) 22697-22705
27. Henderson M.C., Miranda C.L., Stevens J.F., Deinzer M.L., and Buhler D.R. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica 30 (2000) 235-251
28. Jefcoate C.R., Liehr J.G., Santen R.J., Sutter T.R., Yager J.D., Yue W., Santner S.J., Tekmal R., Demers L., Pauley R., Naftolin F., Mor G., and Berstein L. Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl. Cancer Inst. Monog. 27 (2000) 95-112
29. Kim J.H., Stansbury K.H., Walker N.J., Trush M.A., Strickland P.T., and Sutter T.R. Metabolism of benzo[a] pyrene and benzo[a] pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis 19 (1998) 1847-1853
30. Kim J.H., Sherman M.E., Curriero F.C., Guengerich F.P., Strickland P.T., and Sutter T.R. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers and ex-smokers. Toxicol. Appl. Pharmacol. 199 (2004) 210-219
31. Liehr J.G., and Ricci M.J. 4-hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3294-3296
32. Liehr J.G., Fang W.F., Sirbasku D.A., and Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J. Steroid Biochem. 24 (1986) 353-356
33. Liehr J.G., Ricci M.J., Jefcoate C.R., Hannigan E.V., Hokanson J.A., and Zhu B.T. 4-hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9220-9224
34. Mammen J.S., Pittman G.S., Li Y., Abou-Zahr F., Bejjani B.A., Bell D.A., Strickland P.T., and Sutter T.R. Single amino acid mutations but not common polymorphisms, decrease the activity of CYP1B1 against (-) benzo[a]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 24 (2003) 1247-1255
35. Mammen J.S., Kleiner H.E., DiGiovanni J., Sutter T.R., and Strickland P.T. Coumarins are competitive inhibitors of cytochrome P4501B1, with equal potency for allelic variants. Pharmacogenet. Genomics 15 (2005) 183-188
36. Marangoni A.G. Enzyme Kinetics: A Modern Approach (2003), Wiley-Inter Science, New Jersey
37. McFadyen M.C.E., Breeman S., Payne S., Stirk C., Miller I.D., Melvin W.T., and Murray G.I. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J. Histochem. Cytochem. 47 (1999) 1457-1464
38. Mesia-Vela S., Sanchez R.I., Li J.J., Li S.A., Conney A.H., and Kauffman F.C. Catechol estrogen formation in liver microsomes from female ACI and Sprague-Dawley rats: comparison of 2- and 4-hydroxylation revisited. Carcinogenesis 23 (2002) 1369-1372
39. Murray G.I., Taylor M.C., McFadyen M.C.E., McKay J.A., Greenlee W.F., Burke M.D., and Melvin W.T. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57 (1997) 3026-3031
40. Murray G.I., Melvin W.T., Greenlee W.F., and Burke M.D. Regulation, function and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 297-316
41. Muskhelishvili L., Thompson P.A., Kusewitt D.F., Wang C., and Kadlubar F.F. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J. Histochem. Cytochem. 49 (2001) 229-236
42. Pang S., Cao J.Q., Katz B.H., Hayes C.L., Sutter T.R., and Spink D.C. Inductive and inhibitory effects of non-ortho-substituted polychlorinated biphenyls on estrogen metabolism and human cytochromes P450 1A1 and 1B1. Biochem. Pharmacol. 58 (1999) 29-38
43. Piver B., Berthou F., Dreano Y., and Lucas D. Differential inhibition of human cytochrome P450 enzymes by ε-viniferin, the dimmer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci. 73 (2003) 1199-1213
44. Rochat B., Morsman J.M., Murray G.I., Figg W.D., and Mcleod H.L. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?. J. Pharmacol. Exp. Ther. 296 (2001) 537-541
45. Russo J., Hasan Lareef M., Balogh G., Guo S., and Russo I.H. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J. Steroid Biochem. Mol. Biol. 87 (2003) 1-25
46. Rylander-Rudqvist T., Wedren S., Granath F., Humphreys K., Ahlberg S., Weiderpass E., Oscarson M., Ingelman-Sundberg M., and Persson I. Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 24 (2003) 1533-1539
47. Sasaki M., Kaneuchi M., Fujimoto S., Tanaka Y., and Dahiya R. CYP1B1 gene in endometrial cancer. Mol. Cell. Endocrinol. 202 (2003) 171-176
48. Savas Ü., Bhattacharyya K.K., Christou M., Alexander D.L., and Jefcoate C.R. Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. J. Biol. Chem. 269 (1994) 14905-14911
49. Savas U., Carstens C.P., and Jefcoate C.R. Biological oxidations and P450 reactions recombinant mouse CYP1B1 expressed in Escherichia coli exhibits selective binding by polycyclic hydrocarbons and metabolism which parallels C3H10T1/2 cell microsomes but differs from human recombinant CYP1B1. Arch. Biochem. Biophys. 347 (1997) 181-192
50. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., and Sutter T.R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 56 (1996) 2979-2984
51. Shimada T., El-Bayoumy K., Upadhyaya P., Sutter T.R., Guengerich F.P., and Yamazaki H. Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds. Cancer Res. 57 (1997) 4757-4764
52. Shimada T., Yamazaki H., Foroozesh M., Hopkins N.E., Alworth W.L., and Guengerich F.P. Selectivity of polycylic inhibitors for human cytochrome P450s 1A1, 1A2, 1B1. Chem. Res. Toxicol. 11 (1998) 1048-1056
53. Sparfel L., Huc L., Vee M.L., Desille M., Lagadic-Gossmann D., and Fardel O. Inhibition of carcinogen-bioactivating cytochrome P450 1 isoforms by amiloride derivatives. Biochem. Pharmacol. 67 (2004) 1711-1719
54. Spivack S.D., Hurteau G.J., Reilly A.A., Aldous K.M., Ding X., and Kaminky L.S. CYP1B1 expression in human lung. Drug Metab. Dispos. 29 (2001) 916-922
55. Sutter T.R., Tang Y.M., Hayes C.L., Wo Y.P., Jabs E.W., Li X., Yin H., Cody C.W., and Greenlee W.F. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. 69 (1994) 13092-13099
56. Takahashi E., Fujita K., Kamataki T., Kobayashi S.A., Okamoto K., and Negishi T. Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin. Mutat. Res. 508 (2002) 147-156
57. Van Aswegen C.H., Purdy R.H., and Wittliff J.L. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J. Steroid Biochem. 32 (1989) 485-492
58. Walker N.J., Gastel J.A., Costa L.T., Clark G.C., Lucier G.W., and Sutter T.R. Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals. Carcinogenesis 16 (1995) 1319-1327
59. Yano J.K., Koo L.S., Schuller D.J., Li H., Ortiz de Montellano P.R., and Poulos T.L. Crystal structure of a thermophilic cytochrome P450 from the archaeon Sulfolobus olfataricus. J. Biol. Chem. 275 (2000) 31086-31092
60. Zahid M., Kohli E., Saeed M., Rogan E., and Cavalieri E. The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem. Res. Toxicol. 19 (2006) 164-172
61. Zhao Z., Kosinska W., Khmelnitsky M., Cavalieri E.L., Rogan E.G., Chakravarti D., Sacks P.G., and Guttenplan J.B. Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB Rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol. Chem. Res. Toxicol. 19 (2006) 475-479